Max Healthcare Q4 FY26 Results: Key Dates for 2026

What investors are tracking

Max Healthcare Institute (NSE: MAXHEALTH) is preparing to announce its fourth quarter FY26 (Q4 FY26) financial results for the period ended March 31, 2026. The company has indicated that the board of directors is expected to meet in May 2026 to approve the audited financial statements for the quarter and the full year ended March 31, 2026. The board agenda also includes considering a recommendation for a final dividend for FY26, which would require shareholder approval. For investors in the Healthcare and Hospitals segment, the timing and the formal approvals matter because they set the cadence for disclosures, dividend actions, and compliance-related trading restrictions.

Q4 FY26 results date: May 2026 (Expected)

In the company’s event-related disclosures and calendar references provided, Max Healthcare’s Q4 FY26 results are scheduled for May 2026 (Expected). The board meeting is expected to approve the audited consolidated financial statements for the quarter and full year ended March 31, 2026. The company has also repeated that the board meeting date will be announced and published on the company’s website.

While the month is indicated as “expected” rather than a confirmed date, the direction is clear: the company is in the closing phase of the FY26 reporting cycle, and the formal approval process will run through the board meeting. Until the results are declared, key compliance procedures remain in force for designated persons.

Trading window closure and SEBI compliance

Max Healthcare has communicated a trading window closure for designated persons and their immediate relatives from April 1, 2026, until 48 hours after the declaration of financial results for the fourth quarter and full year ending March 31, 2026. The company stated that this action is aligned with SEBI’s Prohibition of Insider Trading Regulations, 2015 and its internal code of conduct.

The disclosure also notes that the board meeting date for considering and approving the results would be communicated separately. This aligns with the typical process where companies first notify exchanges about trading window restrictions and later confirm the meeting date under the relevant disclosure norms.

Dividend expectation: Nil expected

The provided information indicates that the company is expected to consider a final dividend of “Nil expected” at the Q4 FY26 board meeting. If a final dividend is proposed later, it would be subject to shareholder approval at the upcoming Annual General Meeting.

A dividend yield figure of 0.16% is also stated in the material. Beyond that, no dividend amount for FY26 is provided in the text, and the expectation remains that a final dividend may not be recommended.

Board meeting history: recent disclosures

The company’s past board meeting record shown in the material lists several key dates tied to results:

• February 5, 2026: Quarterly Results
• November 14, 2025: Quarterly Results
• August 13, 2025: Quarterly Results
• May 20, 2025: Audited Results and Final Dividend

Separately, Max Healthcare informed BSE that a board meeting was scheduled on February 5, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The company also stated that the results would be made available on its website (www.maxhealthcare.in) following board approval, and that the trading window would remain closed for designated persons until 48 hours after the declaration.

Operational snapshot from the latest referenced quarter

The text includes a press release headline for Max Healthcare’s Q3 performance with specific figures:

• Q3 revenue rose to Rs. 2,608 Cr, registering growth of +10% YoY
• Network Operating EBITDA grew to Rs. 648 Cr
• PAT grew by +9% YoY to Rs. 344 Cr

These numbers are for Q3 (as referenced) and are not presented as Q4 estimates. Still, they provide a recent, company-provided snapshot that investors may use to contextualise the upcoming audited FY26 numbers.

Key facts table

Market context: earnings season and peer timelines

The material also references that TCS declared Q4 FY26 results on April 9, 2026, and Infosys results are scheduled for April 23, 2026. While these are from a different sector, they reflect how closely investors track results timelines during earnings season and why confirmed dates and compliance windows matter.

For Max Healthcare, the focus is on the board’s approval of audited numbers and the confirmation of whether there is any final dividend recommendation. Since the indicated Q4 date is “May 2026 (Expected)”, investors may watch for the exchange filing that confirms the board meeting date and the results date.

Why the event matters

Two elements stand out in the information provided. First, Q4 FY26 results are audited and cover the full year end, which often brings additional disclosures compared with quarterly unaudited results. Second, the trading window closure from April 1, 2026 signals the company’s earnings blackout period under insider trading rules, reducing the risk of non-public information influencing trades by insiders.

The dividend reference is also relevant. The text explicitly says “Nil expected,” which frames expectations ahead of the board meeting and clarifies that any final dividend, if proposed, would still require shareholder approval at the Annual General Meeting.

What to watch next

The next concrete step is a stock exchange announcement confirming the board meeting date in May 2026 and the results schedule. After the board approves the audited statements, the company has said the results will be available on its website. The trading window restriction is expected to lift 48 hours after the results are officially declared.